Loading
A phase 2 trial of TAS-120 in biliary tract cancer, run by Taiho Oncology, Inc., now recruiting.
Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement is a phase 2 interventional study registered as NCT05727176 by Taiho Oncology, Inc., with 120 participants planned, started 2023-07-05 and due to reach its primary completion in 2026-12. Interventions recorded: TAS-120.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Araris Biotech (Taiho) and the tag pipeline.
Shares Araris Biotech (Taiho) and the tag pipeline.
Shares Araris Biotech (Taiho) and the tag pipeline.
Shares Biliary tract cancer (cholangiocarcinoma) and the tag pipeline.
Shares Biliary tract cancer (cholangiocarcinoma) and the tag pipeline.
Shares Biliary tract cancer (cholangiocarcinoma) and the tag pipeline.
Shares Biliary tract cancer (cholangiocarcinoma) and the tag pipeline.
Shares Araris Biotech (Taiho) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/